COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Briefing materials for advisory committee meeting suggest that FDA believes cardiovascular safety issues with Vioxx represent a class effect. Committee will be asked for views on whether COX-2s should stay on the market – after being reminded of "hope" for GI safety advantage that drove development.